Ribociclib (Kisqali)


Indications for Prior Authorization:

  • Indicated in combination with an aromatase inhibitor [i.e., letrozole, exemestane, anastrozole] as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.

Patients must meet the following criteria for the indication(s) above:

  • Prescribed by an oncologist, AND
  • Diagnosis of recurrent or metastatic HR+, HER2- breast cancer, AND
  • Will be used in combination with letrozole, AND
  • Patient is female and postmenopausal


  • 600 mg (three 200 mg tablets) once daily for 21 consecutive days followed by 7 days off to comprise a 28-day cycle
  • Taken with an aromatase inhibitor given continuously throughout the 28-day cycle
  • Dose interruption, reduction, and/or discontinuation may be required based on individual safety and tolerability
  • Dose adjustment for use with strong CYP3A inhibitors and in patients with moderate-severe hepatic impairment: 400 mg once daily


  • 1 year

Last review date: June 12, 2017

WHA is closely monitoring the Coronavirus Disease 2019 (COVID-19). Learn more about COVID-19.